Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination
- PMID: 35214613
- PMCID: PMC8880181
- DOI: 10.3390/vaccines10020154
Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination
Abstract
Vaccination is considered the most important measure to control the COVID-19 pandemic. Extensive follow-up studies with distinct vaccines and populations are able to promote robust and reliable data to better understand the effectiveness of this pharmacologic strategy. In this sense, we present data regarding binding and neutralizing (achieved by surrogate ELISA assay) antibodies throughout time, from vaccinated and previously infected (PI) health care workers (HCW) in Portugal. We analyzed serum samples of 132 HCW, who were vaccinated and with previous SARS-CoV-2 infection. Samples were collected before vaccination (baseline, M1), at second dose vaccine uptake (M2), and 25-70 days (M3) and 150-210 days (M4) after the second dose for vaccinated individuals. The IgG (anti-RBD/S) antibody geometric mean titers found on vaccinated HCW at M2 (GM = 116.1 BAU/mL; CI: 92.3-146.1) were significantly higher than those found on PI HCW at recruitment (M1) (GM = 35.9 BAU/mL; CI:15.4-83.4), and the neutralizing antibodies (nAb) were similar between these groups, of 93.2 UI/mL (95% CI 73.2-118.5) vs. 84.1 UI/mL (95% CI 40.4-155.9), respectively. We detected around 10-fold higher IgG (anti-RBD/S) antibodies titers in M3 when compared with M2, with a slight but significant decrease in titers from 36 days after the second dose vaccine uptake. The increase of nAb titers was correlated with IgG (anti-RBD/S) antibodies titers; however, in contrast to IgG (anti-RBD/S) antibodies titers, we did not detect a decrease in the nAb titer 36 days after a second vaccine dose uptake. At M4, a decrease of 8-fold in binding IgG (anti-RBD/S) and nAb was observed. No significant differences in antibody titers were observed by sex, age or chronic diseases. Our results suggest that IgG (anti-RBD/S) antibodies titers and nAb titers could be correlated, but an ongoing follow up of the cohort is required to better understand this correlation, and the duration of the immune response.
Keywords: COVID-19; health care workers; immunology; neutralizing antibodies.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays.Clin Chem Lab Med. 2021 Dec 16;60(3):456-463. doi: 10.1515/cclm-2021-1247. Print 2022 Feb 23. Clin Chem Lab Med. 2021. PMID: 34911170
-
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.EBioMedicine. 2021 Sep;71:103561. doi: 10.1016/j.ebiom.2021.103561. Epub 2021 Aug 27. EBioMedicine. 2021. PMID: 34455390 Free PMC article.
-
Evaluation of Commercial Anti-SARS-CoV-2 Antibody Assays and Comparison of Standardized Titers in Vaccinated Health Care Workers.J Clin Microbiol. 2022 Jan 19;60(1):e0174621. doi: 10.1128/JCM.01746-21. Epub 2021 Oct 27. J Clin Microbiol. 2022. PMID: 34705539 Free PMC article.
-
Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic.Int J Hyg Environ Health. 2021 Sep;238:113851. doi: 10.1016/j.ijheh.2021.113851. Epub 2021 Sep 25. Int J Hyg Environ Health. 2021. PMID: 34601375 Free PMC article.
-
Kinetics of anti-SARS-CoV-2 responses post complete vaccination with coronavac: A prospective study in 50 health workers.J Public Health Res. 2022 Aug 9;11(3):22799036221104173. doi: 10.1177/22799036221104173. eCollection 2022 Jul. J Public Health Res. 2022. PMID: 35966047 Free PMC article. Review.
Cited by
-
Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022.Emerg Infect Dis. 2023 Feb;29(3):590-594. doi: 10.3201/eid2903.221546. Epub 2023 Feb 2. Emerg Infect Dis. 2023. PMID: 36732078 Free PMC article.
-
Tracking B Cell Memory to SARS-CoV-2 Using Rare Cell Analysis System.Vaccines (Basel). 2023 Mar 26;11(4):735. doi: 10.3390/vaccines11040735. Vaccines (Basel). 2023. PMID: 37112647 Free PMC article.
-
A Low Number of Baselines γδ T Cells Increases the Risk of SARS-CoV-2 Post-Vaccination Infection.Vaccines (Basel). 2024 May 18;12(5):553. doi: 10.3390/vaccines12050553. Vaccines (Basel). 2024. PMID: 38793803 Free PMC article.
-
Dynamics of Antibody Responses after Asymptomatic and Mild to Moderate SARS-CoV-2 Infections: Real-World Data in a Resource-Limited Country.Trop Med Infect Dis. 2023 Mar 23;8(4):185. doi: 10.3390/tropicalmed8040185. Trop Med Infect Dis. 2023. PMID: 37104311 Free PMC article.
-
Neutralizing Antibodies against SARS-CoV-2 Beta and Omicron Variants Inhibition Comparison after BNT162b2 mRNA Booster Doses with a New PETIA sVNT Assay.Diagnostics (Basel). 2023 Feb 26;13(5):889. doi: 10.3390/diagnostics13050889. Diagnostics (Basel). 2023. PMID: 36900033 Free PMC article.
References
-
- WHO . Evaluation of COVID-19 Vaccine Effectiveness. WHO; Geneva, Switzerland: 2021. p. 70.
-
- Infarmed Infarmed COVID-19 -Vacinas Aprovadas (Quadro Resumo) 2021. [(accessed on 20 October 2021)]. Available online: https://www.infarmed.pt/web/infarmed/vacinas-aprovadas.
-
- Carrillo J., Izquierdo-Useros N., Ávila-Nieto C., Pradenas E., Clotet B., Blanco J. Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochem. Biophys. Res. Commun. 2021;538:187–191. doi: 10.1016/j.bbrc.2020.10.108. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous